FDA
-
-
-
-
-
-
-
IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market
-
-
-
-
-
-
-
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer
-
-
-
-
-
-
-
IceCure Medical CFO Ronen Tsimerman to leave after nine years
-
-
-
-
-
-
-
IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
-
-
-
-
-
-
-
IceCure study shows combined therapy achieves 92% lung cancer survival rate
-
-
-
-
-
-
-
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above
-
-
-
-
-
-
-
IceCure Medical Ltd (ICCM) Announces Record Date for Rights Offering for Up to $10 Million
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

